https://www.selleckchem.com/pr....oducts/tucidinostat-
At 3-months of follow-up, there was no significant difference in the clinicoradiographic parameters in all groups. At 3-months of follow-up, there was no significant reduction in whole salivary RANKL and osteoprotegerin levels among individuals in the test and control groups among CP patients with and without CP. The whole salivary RANKL/OPG ratio remains high in patients with poorly-controlled type-2 DM after SRP with or without adjunct PDT. The whole salivary RANKL/OPG ratio remains high in patients with poorly-controll
Like
Comment
Share
